Companies Are Relying On Risk/Benefit Profile To Select Indications For Products, Kendle Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sicker patient populations are willing to tolerate more risk, allowing for a more generous risk/benefit profile, Kendle’s Sietsema says.
You may also be interested in...
Genentech/Biogen Idec Submit Rituxan sBLA For Front-Line Non-Hodgkin’s Lymphoma
Expanded indication could be approved by February 2006, contingent upon a requested priority review.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.
Changes To The NHS: How Can Pharma Best Position Itself?
The U.K.’s Health and Social Care Bill was introduced into Parliament on Jan. 19, offering a new commercial landscape best navigated by pharma through bolstered relationships with general practitioners.